Results 111 to 120 of about 756,852 (217)

Myasthenia gravis in children

Magyar nyelvre súlyos izomgyengeségként fordítható myasthenia gravis görög (myasthenia = izomgyengeség) és latin (gravis = súlyos) szavakból tevődik össze, és egy ritka, krónikus neurológiai betegséget jelöl, ami a vázizmok fáradékonyságával és ...
Mostafa, Mousa
core  

Evaluating inebilizumab in the treatment of generalized myasthenia gravis

Immunotherapy
Myasthenia gravis (MG) is the most common neuromuscular junction disorder. Despite the recent advances in the field, there are still unmet needs. Novel treatments based on new mechanisms of action are now available, including complement inhibitors, neonatal FcRn inhibitors and more recently, B cell-targeted therapies.
openaire   +2 more sources

Case Report: Eculizumab in highly active myasthenia gravis complicated by severe infections

Frontiers in Immunology
Highly active myasthenia gravis refers to a subset of refractory patients who exhibit recurrent exacerbations and crises. Eculizumab, a complement C5 inhibitor, has shown its efficacy and safety for patients with anti-acetylcholine receptor antibody ...
Yufei Deng, Haocheng Luo, Chaoyue Zhang, Li Yang, Shuangshuang Wang, Xuxiang Zhang, Xianni Yan, Xiaojun Yang, Qilong Jiang   +8 more
doaj   +1 more source

[A child with generalized myasthenia gravis successfully treated with tacrolimus].

No to hattatsu = Brain and development, 2007
A 7-year-old girl was diagnosed with generalized myasthenia gravis and became steroid-dependent. Dose of prednisolone could not be reduced to < 2 mg/kg/day on alternate days, despite adverse effects. Thymectomy was avoided. Oral tacrolimus was initiated at 1.0 - 1.3 mg/kg/day.
Goto, Tamako, Mori, Masato, Yamagata, Takanori, Mizuguchi, Masashi, Momoi, Mariko   +4 more
openaire   +2 more sources

Animal models of myasthenia gravis: utility and limitations

, 2016
Renato Mantegazza, Chiara Cordiglieri, Alessandra Consonni, Fulvio Baggi Neurology IV Unit, Neuroimmunology and Neuromuscular Disorders, Foundation IRCCS Neurological Institute “Carlo Besta”, Milan, Italy Abstract: Myasthenia gravis (MG) is ...
Cordiglieri C, Consonni A, Mantegazza R, Baggi F   +3 more
core  

Mycophenolate mofetil for myasthenia gravis: a clear and present controversy

, 2008
Chad Heatwole, Emma CiafaloniDepartment of Neurology, The University of Rochester, Rochester, New York, USAAbstract: Mycophenolate mofetil (MMF) has been used to treat myasthenia gravis (MG) for over 10 years.
Emma Ciafaloni, Chad Heatwole
core  

Familial Myasthenia Gravis

, 1982
Unilateral Ptosis; External OphthalmoplegiaOcular Myasthenia Gravis: Past, Present and Future: https://collections.lib.utah.edu/details?id=2174219Droopy eyelidsIn 1999 Dr. A. G.
Shirley H. Wray, MD, PhD, FRCP
core  

Two‐decade battle with myasthenia gravis: A breakthrough case report on the long‐term success with eculizumab and ravulizumab treatment

Clinical Case Reports
Key Clinical Message This unique case of generalized myasthenia gravis shows sustained stability of a patient's condition for 3 years with eculizumab/ravulizumab treatment following 16 years of refractory disease.
Stefan Quasthoff
doaj   +1 more source

THE ROLE OF VITAMIN D3 SUPPLEMENTATION ON MYASTHENIA GRAVIS COMPOSITE SCALE: A CASE REPORT

Jurnal Kedokteran dan Kesehatan
Myasthenia Gravis (MG) is a rare chronic autoimmune disorder triggered by pathogenic IgG autoantibodies and complement activation. Common clinical manifestations include ocular muscle weakness, dysphagia, dysarthria, dysphonia, limb muscle weakness ...
Meidistya Ayu Mardhiani, Wina Sinaga, Diyah Eka Andayani   +2 more
doaj   +1 more source

Treatment of Ocular Myasthenia Gravis

, 2019
Myasthenia gravis is caused by pathogenic autoantibodies to the postsynaptic neuromuscular junction. Clinically, this may affect any of the skeletal muscles causing variable weakness, which worsens with continued muscle activity. Ocular myasthenia gravis
Michael Lee
core